A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. | Progress in brain research | 25 October 2018
Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.
Corkery, J. M. | Progress in brain research | 12 October 2018
LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice.
Alper, K., Dong, B., Shah, R., Sershen, H., & Vinod, K. Y. | Frontiers in pharmacology | 31 August 2018
Therapeutic Potential Ascribed to Ayahuasca by Users in the Czech Republic
Horák, M., Hasíková, L., & Verter, N. | Journal of psychoactive drugs | 30 August 2018
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. | Journal of Psychopharmacology | 25 June 2018
Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes
Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. | Frontiers in Pharmacology | 5 June 2018
Psychedelic therapy as a complementary treatment approach for alcohol use disorders
Eischens, P., & Atherton, W. L. | Journal of Psychedelic Studies | 30 May 2018
Ayahuasca and Its DMT- and β-carbolines – Containing Ingredients Block the Expression of Ethanol-Induced Conditioned Place Preference in Mice: Role of the Treatment Environment
Cata-Preta, E. G., Serra, Y. A., Moreira-Junior, E. D. C., Reis, H. S., Kisaki, N. D., Libarino-Santos, M., ... & Costa, J. L. | Frontiers in pharmacology | 29 May 2018
The epidemiology of 5-methoxy- N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018
Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine
Malcolm, B. J., Polanco, M., & Barsuglia, J. P. | Journal of psychoactive drugs | 2 April 2018
Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: an exploratory study
Dorsen, C., Palamar, J., & Shedlin, M. G. | Addiction Research & Theory | 30 March 2018
The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions
Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. | Frontiers in Pharmacology | 21 February 2018
Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., ... & Mennenga, S. E. | Frontiers in Pharmacology | 20 February 2018
Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation
Curran, H. V., Nutt, D., & de Wit, H. | Psychopharmacology | 14 February 2018
The Effects of Ibogaine on Uterine Smooth Muscle Contractions: Relation to the Activity of Antioxidant Enzymes
Oreščanin-Dušić, Z., Tatalović, N., Vidonja-Uzelac, T., Nestorov, J., Nikolić-Kokić, A., Mijušković, A., ... & Blagojević, D. | Oxidative medicine and cellular longevity | 11 February 2018
Evaluating the abuse potential of psychedelic drugs for medical use in humans
Heal, D. J., Gosden, J., & Smith, S. L. | Neuropharmacology | 7 February 2018
Ayahuasca: Psychological And Physiologic Effects, Pharmacology And Potential Uses In Addiction And Mental Illness
Hamill, J., Hallak, J., Dursun, S. M., & Baker, G. | Current neuropharmacology | 24 January 2018
Ketamine for the treatment of addiction: Evidence and potential mechanisms
Ezquerra-Romano, I. I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. | Neuropharmacology | 12 January 2018
A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study
Dakwar, E., Nunes, E. V., Hart, C. L., Hu, M. C., Foltin, R. W., & Levin, F. R. | Neuropharmacology | 5 January 2018
Breaking the cycle of opioid use disorder with Ibogaine
C. Mash, D. | The American Journal of Drug and Alcohol Abuse | 7 December 2017
Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine
Fattore, L., Piva, A., Zanda, M. T., Fumagalli, G., & Chiamulera, C. | Psychopharmacology | 25 November 2017
Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey
Lawn, W., Hallak, J. E., Crippa, J. A., Santos, R., Porffy, L., Barratt, M. J., ... & Morgan, C. J. | Scientific reports | 9 November 2017
Why MDMA therapy for alcohol use disorder? And why now?
Sessa, B. | Neuropharmacology | 7 November 2017
Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning
Davis, A. K., Barsuglia, J. P., Windham-Herman, A. M., Lynch, M., & Polanco, M. | Journal of Psychedelic Studies | 17 October 2017
Psychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. | Trends in Pharmacological Sciences | 22 September 2017